We observed that the percentage of ccRCC patients harboring MAP3K8 mutation is 0.3% (1 of 370 patients) from the TIMER2.0 dataset (Supplementary Figure 2A), whereas data from cBioPortal server suggested that 0.2% (1 of 511) to 11.5% (9 of 78) ccRCC patients had somatic MAP3K8 mutation (Figure 4A). Here, MAP3K8 is linked to nonpapillary renal cell carcinoma.